{"task_id": "2950456a1a975c8a", "source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 161/464)", "text": "ONT\u2019D)\nCLINICAL FEATURES (CONT\u2019D)\nEosinophilia\n149\n\n--- Page 171 ---\nThrombocytosis\nNEJM 2004 350:12\nDIFFERENTIAL DIAGNOSIS\nPRIMARY\n(clonal\nthrombocytosis)\nessential\nthrombocythemia, chronic myelogenous leukemia,\npolycythemia rubra vera, myeloid metaplasia with\nor without myelofibrosis, prefibrotic myelofibrosis\nSECONDARY (reactive)\n\u0002\nMALIGNANCY\n\u0002\nINFECTIONS\n\u0002\nCONNECTIVE TISSUE DISEASE\n\u0002\nDRUG\nREACTIONS\nvincristine, all trans retinoic\nacid, cytokines, growth factors\n\u0002\nOTHERS\niron\ndeficiency,\nacute\nblood\nloss,\nhemolytic anemia, rebound from thrombocyto\npenia, splenectomy\nPATHOPHYSIOLOGY\nDEFINITION\nplatelets >450\u0003103/mL\nRelated Topic\nMyeloproliferative Disorders (p. 165)\nCLINICAL FEATURES\nDISTINGUISHING FEATURES BETWEEN PRIMARY AND SECONDARY THROMBOCYTOSIS\nPrimary\nSecondary\nUnderlying disease\nN\nY\nDigital ischemia/CVA\nY\nN\nThrombosis\nY\nN\nBleeding\nY\nN\nSplenomegaly\nY (40%)\nN\nPeripheral smear\nGiant platelets\nNormal platelets\nPlatelet function\nAbnormal\nNormal\nBM megakaryocytes\n\", giant\n\", normal\nINVESTIGATIONS\nBASIC\n\u0002\nLABS\nCBCD, peripheral smear, PTT, INR, Fe, fer\nritin, TIBC, % sat, ESR (secondary cause), CRP\n(secondary cause)\nSPECIAL\n\u0002\nBONE MARROW BIOPSY\nDIAGNOSTIC ISSUES\nIMPORTANT\nPEARL\nremember\nthat\nessential\nthrombocythemia is a diagnosis of exclusion. Thus,\nit is important to consider and rule out iron defi\nciency, occult malignancy, and another myeloproli\nferative disorder before making this diagnosis\nMANAGEMENT\nESSENTIAL THROMBOCYTHEMIA\nobservation if\nasymptomatic and low risk of thrombosis, defined\nas age < 60 and no cardiovascular risk factors. For\nall others with platelet counts >450\u0003103/mL, use ASA\n81 mg PO daily (low dose) plus hydroxyurea (or\nanagrelide) targeting normalization of the platelet\ncount. When the platelets are >1500\u0003103/mL, plate\nletpheresis must be started for active ischemia and\ncan be considered for use in asymptomatic patients\nat risk for coronary and/or cerebral ischemic events\nSECONDARY CAUSES\ntreat underlying cause\n150\nThrombocytosis", "text_length": 1992, "metadata": {"source": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf (Part 161/464)", "type": "chunk", "chunk_index": 160, "total_chunks": 464, "uploaded_by": "admin@admin.com", "upload_date": "2025-12-11T18:40:09.467243", "document_uuid": "fda2cab4-cdd9-4015-af24-46fd62c86d94", "filename": "Approach to Internal Medicine_ A Resource Book for Clinical Practice ( PDFDrive ).pdf", "category": "medical_pdf", "section": "body", "year": null, "outdated": false, "document_id": "fda2cab4-cdd9-4015-af24-46fd62c86d94"}, "created_at": "2025-12-11T18:40:09.468041", "status": "complete", "chunks_added": 2}